FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193667053> ?p ?o ?g. }

• W3193667053 endingPage "S84" @default.
• W3193667053 startingPage "S83" @default.
• W3193667053 abstract "Objectives: Given its rarity, the optimal management of patients with endometrial cancer extending to the parametria, vagina or pelvic sidewall in the absence of lymph node metastasis is not well defined. We aimed to investigate the outcomes of patients with stage IIIB endometrioid cancer following hysterectomy based on different adjuvant treatment strategies. Methods: Patients with no history of another tumor diagnosed between 2004 and 2015 with stage IIIB endometrioid adenocarcinoma of the uterus who underwent primary hysterectomy, had negative lymph nodes and at least one month of follow-up were selected from the National Cancer Database. Overall survival between patients who were observed or received chemotherapy-only (CT), radiotherapy-only (RT) and chemoradiation (CRT) were compared with the log-rank test after generation of Kaplan-Meier curves. A Cox multivariate model was constructed to control for confounders. Results: A total of 717 patients with a median age of 64 years who met the inclusion criteria were identified. Radical hysterectomy was performed for 17% of cases. Data on margin status was available for 638 cases; 73.5% had negative margins. Tumor was extending to the parametria for 239 (33.3%) patients, to the vagina for 235 (32.8%) cases, to the pelvic sidewall for 102 (14.2%) cases, and was abutting bladder/colon (without invasion) for 55 cases (7.7%) while 86 patients (12%) had stage IIIB not otherwise specified. A total of 147 (20.5%) patients did not receive adjuvant treatment, while 118 (16.5%) received chemotherapy-alone, 206 (28.7%) received radiotherapy-alone and 246 (34.3%) received chemoradiation. Tumor grade and presence of comorbidities was comparable between the groups. Five-year OS rates for patients who did not receive adjuvant treatment was 49.8% compared to 56% for those who had chemotherapy-alone, 60% for those who had radiotherapy-alone and 76.2% for those who received chemoradiation, p<0.001. After controlling for patient age, race, presence of comorbidities, insurance status, tumor grade, and margin status, compared to observation alone, patients who received chemoradiation (HR: 0.36, 95% CI: 0.25, 0.52) and radiation-alone (HR: 0.64, 95% CI: 0.46, 0.89) but not chemotherapy-alone (HR: 0.81, 95% CI: 0.59, 1.27) had better survival. Compared to radiation-alone, chemoradiation was associated with better survival (HR: 0.56, 95% CI: 0.39, 0.81). Conclusions: Chemoradiation is associated with better survival outcomes for patients with stage IIIB endometrial cancer Given its rarity, the optimal management of patients with endometrial cancer extending to the parametria, vagina or pelvic sidewall in the absence of lymph node metastasis is not well defined. We aimed to investigate the outcomes of patients with stage IIIB endometrioid cancer following hysterectomy based on different adjuvant treatment strategies. Patients with no history of another tumor diagnosed between 2004 and 2015 with stage IIIB endometrioid adenocarcinoma of the uterus who underwent primary hysterectomy, had negative lymph nodes and at least one month of follow-up were selected from the National Cancer Database. Overall survival between patients who were observed or received chemotherapy-only (CT), radiotherapy-only (RT) and chemoradiation (CRT) were compared with the log-rank test after generation of Kaplan-Meier curves. A Cox multivariate model was constructed to control for confounders. A total of 717 patients with a median age of 64 years who met the inclusion criteria were identified. Radical hysterectomy was performed for 17% of cases. Data on margin status was available for 638 cases; 73.5% had negative margins. Tumor was extending to the parametria for 239 (33.3%) patients, to the vagina for 235 (32.8%) cases, to the pelvic sidewall for 102 (14.2%) cases, and was abutting bladder/colon (without invasion) for 55 cases (7.7%) while 86 patients (12%) had stage IIIB not otherwise specified. A total of 147 (20.5%) patients did not receive adjuvant treatment, while 118 (16.5%) received chemotherapy-alone, 206 (28.7%) received radiotherapy-alone and 246 (34.3%) received chemoradiation. Tumor grade and presence of comorbidities was comparable between the groups. Five-year OS rates for patients who did not receive adjuvant treatment was 49.8% compared to 56% for those who had chemotherapy-alone, 60% for those who had radiotherapy-alone and 76.2% for those who received chemoradiation, p<0.001. After controlling for patient age, race, presence of comorbidities, insurance status, tumor grade, and margin status, compared to observation alone, patients who received chemoradiation (HR: 0.36, 95% CI: 0.25, 0.52) and radiation-alone (HR: 0.64, 95% CI: 0.46, 0.89) but not chemotherapy-alone (HR: 0.81, 95% CI: 0.59, 1.27) had better survival. Compared to radiation-alone, chemoradiation was associated with better survival (HR: 0.56, 95% CI: 0.39, 0.81). Chemoradiation is associated with better survival outcomes for patients with stage IIIB endometrial cancer" @default.
• W3193667053 created "2021-08-30" @default.
• W3193667053 creator A5003929069 @default.
• W3193667053 creator A5004482380 @default.
• W3193667053 creator A5006476844 @default.
• W3193667053 creator A5026950248 @default.
• W3193667053 creator A5027202188 @default.
• W3193667053 creator A5027249949 @default.
• W3193667053 creator A5036514898 @default.
• W3193667053 creator A5068319278 @default.
• W3193667053 creator A5078818153 @default.
• W3193667053 date "2021-08-01" @default.
• W3193667053 modified "2023-09-23" @default.
• W3193667053 title "Adjuvant treatment for patients with stage IIIB endometrioid endometrial cancer following hysterectomy" @default.
• W3193667053 doi "https://doi.org/10.1016/s0090-8258(21)00799-x" @default.
• W3193667053 hasPublicationYear "2021" @default.
• W3193667053 type Work @default.
• W3193667053 sameAs 3193667053 @default.
• W3193667053 citedByCount "0" @default.
• W3193667053 crossrefType "journal-article" @default.
• W3193667053 hasAuthorship W3193667053A5003929069 @default.
• W3193667053 hasAuthorship W3193667053A5004482380 @default.
• W3193667053 hasAuthorship W3193667053A5006476844 @default.
• W3193667053 hasAuthorship W3193667053A5026950248 @default.
• W3193667053 hasAuthorship W3193667053A5027202188 @default.
• W3193667053 hasAuthorship W3193667053A5027249949 @default.
• W3193667053 hasAuthorship W3193667053A5036514898 @default.
• W3193667053 hasAuthorship W3193667053A5068319278 @default.
• W3193667053 hasAuthorship W3193667053A5078818153 @default.
• W3193667053 hasConcept C121608353 @default.
• W3193667053 hasConcept C126322002 @default.
• W3193667053 hasConcept C141071460 @default.
• W3193667053 hasConcept C143998085 @default.
• W3193667053 hasConcept C146357865 @default.
• W3193667053 hasConcept C151730666 @default.
• W3193667053 hasConcept C2777088508 @default.
• W3193667053 hasConcept C2777416452 @default.
• W3193667053 hasConcept C2778220009 @default.
• W3193667053 hasConcept C2778515176 @default.
• W3193667053 hasConcept C2779494336 @default.
• W3193667053 hasConcept C2780435969 @default.
• W3193667053 hasConcept C2780849966 @default.
• W3193667053 hasConcept C2910227796 @default.
• W3193667053 hasConcept C509974204 @default.
• W3193667053 hasConcept C71924100 @default.
• W3193667053 hasConcept C86803240 @default.
• W3193667053 hasConceptScore W3193667053C121608353 @default.
• W3193667053 hasConceptScore W3193667053C126322002 @default.
• W3193667053 hasConceptScore W3193667053C141071460 @default.
• W3193667053 hasConceptScore W3193667053C143998085 @default.
• W3193667053 hasConceptScore W3193667053C146357865 @default.
• W3193667053 hasConceptScore W3193667053C151730666 @default.
• W3193667053 hasConceptScore W3193667053C2777088508 @default.
• W3193667053 hasConceptScore W3193667053C2777416452 @default.
• W3193667053 hasConceptScore W3193667053C2778220009 @default.
• W3193667053 hasConceptScore W3193667053C2778515176 @default.
• W3193667053 hasConceptScore W3193667053C2779494336 @default.
• W3193667053 hasConceptScore W3193667053C2780435969 @default.
• W3193667053 hasConceptScore W3193667053C2780849966 @default.
• W3193667053 hasConceptScore W3193667053C2910227796 @default.
• W3193667053 hasConceptScore W3193667053C509974204 @default.
• W3193667053 hasConceptScore W3193667053C71924100 @default.
• W3193667053 hasConceptScore W3193667053C86803240 @default.
• W3193667053 hasLocation W31936670531 @default.
• W3193667053 hasOpenAccess W3193667053 @default.
• W3193667053 hasPrimaryLocation W31936670531 @default.
• W3193667053 hasRelatedWork W2014812463 @default.
• W3193667053 hasRelatedWork W2093079199 @default.
• W3193667053 hasRelatedWork W2431685244 @default.
• W3193667053 hasRelatedWork W2615107578 @default.
• W3193667053 hasRelatedWork W2914750258 @default.
• W3193667053 hasRelatedWork W2944462570 @default.
• W3193667053 hasRelatedWork W3104537559 @default.
• W3193667053 hasRelatedWork W3208630897 @default.
• W3193667053 hasRelatedWork W4230719942 @default.
• W3193667053 hasRelatedWork W4242475497 @default.
• W3193667053 hasVolume "162" @default.
• W3193667053 isParatext "false" @default.
• W3193667053 isRetracted "false" @default.
• W3193667053 magId "3193667053" @default.
• W3193667053 workType "article" @default.